Company intelligence / Profile preview

TaiGen Biopharmaceuticals

Ownership: Private
Employees: ~70
Development stage: Other

Overview

TaiGen has successfully commercialized its lead antibiotic Taigexyn® (nemonoxacin), which has received market approval in China and Taiwan. Its antiviral TG-1000 completed a phase III trial with an NDA filed in China in 2024. Furaprevir remains in phase III trials for hepatitis C. Burixafor is in phase II trials as a stem cell mobilizer.

Therapeutic areas: HematologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

TG-4318

Unknown

Partnerships

GPCR(South Korea)R‑Pharm(Russia/CIS)Productos Científicos(Latin America)Holding Distribution(Taiwan)previously Procter & Gamble Pharmaceuticals(licensing of nemonoxacin)Joincare Pharmaceutical(partnered on TG‑1000)

Beyond the preview

Go deeper on TaiGen Biopharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TaiGen Biopharmaceuticals.